Status:

TERMINATED

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Lead Sponsor:

Johns Hopkins University

Collaborating Sponsors:

Cardinal Health

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. ...

Detailed Description

This is a phase 4 single-center, open-label, single-arm study evaluating the ability of 99mTc-TM to identify clipped nodes in primary breast cancer patients receiving NAC and subsequent Sentinel Lymph...

Eligibility Criteria

Inclusion

  • The patient has provided written informed consent with HIPAA authorization.
  • The patient is female or male and ≥18 years of age at the time of consent.
  • The patient has been diagnosed with invasive Stage 2-3 breast cancer (T1-3; N1-2).
  • The patient has no history of inflammatory breast cancer.
  • The patient has no matted node on examination (N3).
  • The patient is eligible for neoadjuvant chemotherapy (NAC).
  • The patient is a candidate for surgical intervention, with sentinel lymph node assessment being a part of the surgical plan.
  • If of childbearing potential, the patient has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.
  • The patient has no known allergies or hypersensitivity to 99mTc-TM, BD, or India ink.

Exclusion

  • The patient is pregnant or lactating.
  • The patient has clinical and/or radiological evidence of metastatic or systemic disease. Oligo metastatic disease is acceptable (one organ and controlled).

Key Trial Info

Start Date :

March 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 30 2023

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT05236387

Start Date

March 1 2022

End Date

June 30 2023

Last Update

February 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Johns Hopkins Bayview Hospital

Baltimore, Maryland, United States, 21224